In a surprising turn, Anne Wojcicki's nonprofit, TTAM Research Institute, has acquired 23andMe for $305 million after its bankruptcy. This acquisition addresses concerns about genetic data privacy while aiming to uphold the company's mission.
Anne Wojcicki's nonprofit has won the bid to buy 23andMe, raising critical questions about the future of genetic data privacy. Experts warn that sensitive DNA information could be at risk.
In a groundbreaking move, 27 states and D.C. have filed a lawsuit to prevent 23andMe from selling customer genetic data without consent. This legal battle raises significant privacy concerns for users.
Hims & Hers Health is set to acquire European telehealth platform Zava, aiming to expand its services across Europe. The deal promises to add 1.3 million customers and enhance access to affordable medications in Ireland, France, and Germany.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
Pharma faces a daunting challenge as Trump takes bold steps to cut drug prices. With RFK Jr. praising the move, is bipartisanship on the horizon or will the industry fight back?
In a bold move, President Trump is set to sign an executive order mandating the U.S. health department to negotiate lower drug prices with pharmaceutical companies. This could drastically change healthcare costs for millions of Americans.
In a groundbreaking move, President Trump has issued an executive order aimed at ending the price discrimination faced by American consumers in the pharmaceutical market. This order seeks to ensure that Americans pay the same low prices for medications as those in other developed nations, addressing the long-standing issue of subsidizing global pharmaceutical profits.
President Trump unveils a groundbreaking executive order aimed at slashing U.S. drug prices by matching them to those in developed countries. Will this initiative reshape the pharmaceutical landscape and benefit American patients?
In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
